First Tracks Biotherapeutics, Inc. (TRAX)

Price$38.47Cached quoteAs of 2026-09-16 11:39 UTC

AI: Overvalued

Price checkThe market price leaves little downside protection before First Tracks proves its lead medicine works.

With 35.39 million shares outstanding, the observed price implies a total stock-market value near $1.29 billion. Subtracting June net cash—cash minus debt—of $163.7 million leaves about $1.13 billion assigned to the drug candidates, despite no revenue, profit, or patient-effectiveness data from lead program ANB033. The shares also trade at roughly 7.9 times net cash and about 2.6 times April’s financing price. That valuation requires meaningful clinical success, so a conservative value approach finds the shares overvalued.

Big pictureLosses are shrinking, but today's cash use cannot support the pipeline indefinitely without new funding.

Second-quarter net loss improved to $33.4 million from $42.4 million a year earlier, while operating cash use fell to $31.9 million from $38.6 million. First-half operating cash use was $64.5 million. At the latest quarterly pace, June cash covers roughly five quarters, shorter than management’s stated runway into the second quarter of 2028; earlier separation costs make that comparison imperfect. This is not an economically cyclical business: value changes mainly around trial results, while weak funding markets could raise dilution risk.

Business strengthA clean balance sheet buys time, while an unproven pipeline limits its protective value.

June cash of $168.0 million dwarfed $4.3 million of debt and $14.3 million of total liabilities, providing meaningful near-term resilience. ANB033 entered patient testing after an 80-person healthy-volunteer study found no dose-limiting safety problems. Rosnilimab previously produced about 90% reductions in targeted harmful T cells in blood and joint tissue. However, First Tracks earns no product revenue, ANB033’s decisive patient data remain pending, and management is seeking partnership or financing options for rosnilimab rather than funding it alone.

What could change the storyStrong celiac results could justify today's premium, while weak data would expose cash-backed downside.

The clearest test is ANB033’s 30-patient celiac gluten-challenge readout, expected in the fourth quarter of 2026, followed by a 40-patient healing cohort in early 2027. Clear prevention or repair of intestinal damage with acceptable safety would support a valuable multi-disease program; an unclear result would leave the current premium hard to defend. April’s 5.79 million-share financing raised about $80 million but expanded the original 29.10 million-share base by nearly 20%. Further trials may require more dilution, meaning each existing share owns less; no buybacks or dividends offset it.

AI: News

Peer Trial Validates TargetA rival medicine produced positive patient results, strengthening belief in the same biological target used by ANB033.

On July 9, Forte Biosciences reported that FB102 improved a vitiligo measure by 29.6% from baseline at week 24 in a placebo-controlled early-stage trial, with statistical significance. First Tracks rose about 56% that session on unusually heavy trading. Contemporary reporting described the rival result as a constructive signal because both medicines block CD122. That connection is an inference, not direct evidence: FB102 is a different antibody, and the tested disease was vitiligo rather than ANB033’s current celiac trial.

Forte Bought For BillionsA major biotechnology buyer paid heavily for a rival program, lifting expectations for First Tracks' similar approach.

On July 27, argenx agreed to buy Forte for roughly $2.2 billion, primarily adding its anti-CD122 medicine FB102. First Tracks gained about 18% that day. The timing is consistent with investors treating the deal as outside validation of CD122 and a valuation reference for ANB033, but it does not prove causation or equal worth. Forte already had positive patient data in celiac disease and vitiligo, whereas ANB033 had not yet shown patient effectiveness.

Celiac Trial AdvancesRegulators granted faster-review status as enrollment milestones brought the lead medicine closer to decisive patient results.

On August 12, First Tracks said U.S. regulators granted ANB033 Fast Track status for celiac disease and that the 30-patient gluten-challenge group had completed enrollment. Results remain scheduled for the fourth quarter of 2026; a second group of up to 40 patients is expected to report in early 2027. Management also said existing cash should support operations into the second quarter of 2028. Faster review improves regulatory access but does not prove effectiveness or approval. Shares slipped about 1% that day, so trading did not confirm a positive revaluation.

Loading local price history

Revenue

2023

2024

Net income

2023

2024

Free cash flow

2023

2024

Total cash / debt

CashTotal debt

2023

2024

Financial statements

	2024	2023
Revenue	$0	$0
Research & development	$152.3M	$97.6M
Operating expenses	$181.1M	$118.5M
Operating income	−$181.1M	−$118.5M
EBITDA	−$178.7M	−$116.1M
Net income	−$163.7M	−$106.2M
Basic EPSper basic share	—	-$3.05
Diluted EPSper diluted share	—	-$3.05

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

8.97%of listed shares

EcoR1 Capital, LLC3.17M shares · Jun 30, 2026

View holders

Top 20 reported holders of TRAX
Holder	% owned
EcoR1 Capital, LLC	8.97%3.17M shares
TCG Crossover Management, LLC	8.18%2.9M shares
FMR LLC	5.80%2.05M shares
Affinity Asset Advisors, LLC	5.74%2.03M shares
BlackRock, Inc.	5.55%1.96M shares
Trails Edge Capital Partners, LP	4.28%1.51M shares
VANGUARD CAPITAL MANAGEMENT LLC	4.10%1.45M shares
Jupiter Topco LLC	3.08%1.09M shares
Vestal Point Capital, LP	2.86%1.01M shares
Woodline Partners LP	2.59%917.18K shares
Sanofi	2.32%821.92K shares
MORGAN STANLEY	2.21%781.53K shares
683 Capital Management, LLC	2.12%750K shares
ADAGE CAPITAL PARTNERS GP, L.L.C.	2.06%729K shares
Balyasny Asset Management L.P.	2.02%714.95K shares
GEODE CAPITAL MANAGEMENT, LLC	1.98%702.09K shares
BANK OF AMERICA CORP /DE/	1.83%647.96K shares
STEMPOINT CAPITAL LP	1.76%622.72K shares
Palo Alto Investors LP	1.71%603.49K shares
Sofinnova Investments, Inc.	1.60%565.2K shares